Eli Lilly said on Monday it has lowered the price of single-dose vials of its popular obesity drug Zepbound to make the treatment more affordable for U.S. patients, as demand for weight-loss therapies surge.
Patients with a prescription can now buy the starting dose of 2.5 mg for $299 per month, down from $349, through LillyDirect, the drugmaker’s online healthcare platform.
